Repository logo
 
Publication

Systolic Time Ratio Measured by Impedance Cardiography Accurately Screens Left Ventricular Diastolic Dysfunction in Patients with Arterial Hypertension

dc.contributor.authorNazário Leão, R
dc.contributor.authorMarques da Silva, P
dc.contributor.authorBranco, LM
dc.contributor.authorFonseca, H
dc.contributor.authorBento, B
dc.contributor.authorAlves, M
dc.contributor.authorVirella, D
dc.contributor.authorPalma Reis, R
dc.date.accessioned2018-01-05T16:16:35Z
dc.date.available2018-01-05T16:16:35Z
dc.date.issued2017
dc.description.abstractBACKGROUND: The use of impedance cardiography (ICG) may play a role in the assessment of cardiac effects of hypertension (HT), especially its hemodynamic features. Hypertensive heart disease involves structural changes and alterations in left ventricular geometry that end up causing systolic and/or diastolic dysfunction. The IMPEDDANS study aims to assess the usefulness of ICG for the screening of left ventricular diastolic dysfunction (LVDD) in patients with HT. METHODS: Patients with HT were assessed by echocardiography and ICG. Receiver-operating characteristic curve and the area under the curve were used to assess the discriminative ability of the parameters obtained by ICG to identify LVDD, as diagnosed by echocardiography. RESULTS: ICG derived pre-ejection period (PEP), left ventricle ejection time (LVET), systolic time ratio (STR) and D wave were associated (p < 0.001) with LVDD diagnosis, with good discriminative ability: PEP (AUC 0.81; 95% CI 0.74-0.89), LVET (AUC 0.82; 95% CI 0.75-0.88), STR (AUC 0.97; 95% CI 0.94-1.00) and presence of D wave (AUC = 0.87; 95% CI 0.82-0.93). STR ≥ 0.30 outperformed the other parameters (sensitivity of 98.0%, specificity of 90.2%, positive predictive value of 95.2%, and negative predictive value of 96.1%). CONCLUSION: The ICG derived value of STR allows the accurate screening of LVDD in patients with HT. It might as well be used for follow up assessment. TRIAL REGISTRATION: The study protocol was retrospectively registered as IMPEDDANS on ClinicalTrials.gov (ID: NCT03209141) on July 6, 2017.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationClin Hypertens. 2017 Dec 27;23:28pt_PT
dc.identifier.doi10.1186/s40885-017-0084-ypt_PT
dc.identifier.urihttp://hdl.handle.net/10400.17/2836
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherBioMed Centralpt_PT
dc.subjectHSJ MEDpt_PT
dc.subjectHSM MEDpt_PT
dc.subjectHSM CARpt_PT
dc.subjectCHLC CINVpt_PT
dc.subjectArterial Hypertensionpt_PT
dc.subjectDiastolic Dysfunctionpt_PT
dc.subjectImpedance Cardiographypt_PT
dc.subjectSystolic Time Ratiopt_PT
dc.subjectScreeningpt_PT
dc.titleSystolic Time Ratio Measured by Impedance Cardiography Accurately Screens Left Ventricular Diastolic Dysfunction in Patients with Arterial Hypertensionpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.issue1pt_PT
oaire.citation.startPage28pt_PT
oaire.citation.titleClinical Hypertensionpt_PT
oaire.citation.volume23pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Clin Hypert 2017.pdf
Size:
1.05 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: